---
schema_version: "secwatch.filing_event.v1"
accession: "0001636422-24-000004"
form_type: "8-K"
ticker: "HCAT"
cik: "0001636422"
company_name: "Health Catalyst, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:20:46.930594+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Health Catalyst reports preliminary 2023 revenue and EBITDA above guidance; guides 2024 EBITDA ~$25M

## Summary
- Preliminary Q4 2023 total revenue above guidance midpoint (range $70.1M–$75.1M); Adjusted EBITDA at or above midpoint ($0.3M–$2.3M).
- Preliminary FY 2023 total revenue above guidance midpoint ($291M–$296M); Adjusted EBITDA at or above midpoint ($10M–$12M).
- 2023 Dollar-Based Retention Rate approx 100%, below forecast 102%-110%, due to timing delays on large TEMS expansions.
- Anticipates 2024 Adjusted EBITDA of ~$25M and 2025 Adjusted EBITDA margin target of 10% or greater.
- Expects improvement in 2024 net new DOS Subscription Client bookings and retention rate relative to 2023.

## SEC filing metadata
- accession: 0001636422-24-000004
- form_type: 8-K
- ticker: HCAT
- cik: 0001636422
- company_name: Health Catalyst, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636422/000163642224000004/0001636422-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636422/000163642224000004/hcat-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636422-24-000004
- JSON: https://secwatch.observer/filing/0001636422-24-000004.json
- Plain text: https://secwatch.observer/filing/0001636422-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.